Boron-containing drugs labeled with radionuclides and their preparation and application
The radionuclides are labeled through polymerization reaction of dopamine derivatives and boron-containing compounds to form radionuclides with moderate particle size, which solves the problems of poor stability and loss of targeting characteristics of labeled nuclides in the prior art, and achieves high efficiency , stable development of targeted radiopharmaceuticals and integrated application of diagnosis and treatment.
Patent Information
- Application Number
- CN202310131162.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-17
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-02-17
AI Technical Summary
The existing targeted radiopharmaceutical carriers have poor efficiency and stability on labeled nuclides, and the targeting characteristics after labeling are lost, resulting in slow progress in the development of targeted radiopharmaceuticals.
Dopamine and its derivatives are polymerized with boron-containing compounds, and radionuclides are labeled on boron-containing drugs through complexation or covalent bonding, forming radionuclides labeled boron-containing drugs with particle size of 50-1000nm, achieving high efficiency, Stable labeling and maintain targeting properties.
Achieved efficient labeling rates of a variety of radionuclides (such as 68Ga, 67Ga, 90Y, 177Lu, etc., maintain stability in normal saline and phosphate buffer, can enter cells and tumors, and has tumor-targeting , suitable for treatment and imaging, imaging markers help drug distribution research and treatment effect prediction.
Smart Images

Figure CN116077685B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of radiopharmaceuticals, and in particular relates to a boron-containing drug labeled with a radionuclide, and a preparation method and application thereof. Background Art
[0002] Local targeted internal irradiation therapy is an internal irradiation therapy that uses a carrier to precisely deliver radionuclides into the local tumor, thereby achieving treatment through the rays emitted by the radionuclides. Due to its outstanding therapeutic effect, it plays an important role in the treatment of diseases such as tumors and is one of the current hot research directions. At present, there are methods, technologies or drugs that use microspheres, sealed metal seed sources, small molecules, antibodies, peptides, nanomedicines, etc. as carriers of radionuclides to achieve local precision internal irradiation therapy. The most core technical difficulties in developing targeted radioactive drugs are: 1. Designing and developing carriers with good targeting properties; 2. Realizing efficient and stable labeling of radionuclides on carriers with good targeting properties, and the carrier of the labeled nuclide still maintains the characteristics of good targeting of target lesions or tumor cells.
[0003] At present, most of the targeted drug carriers such as small molecules, antibodies, and peptides in clinical applications have problems such as difficulty in achieving efficient and stable labeling of nuclides, poor stability after labeling, and loss of targeting properties after labeling. It is precisely because of the high technical difficulty that the development of targeted radioactive drugs has been relatively slow and lagging. Summary of the invention
[0004] In order to solve the technical problems in the background technology, the purpose of the present invention is to provide a radioactive nuclide labeled boron-containing drug and its preparation and application, the radioactive drug can label 68 Ga, 67 Ga, 64 Cu, 67 Cu, 89 Zr, 89 Sr. 90 Y. 177 Lu, 111 In, 165 Dy, 166 Ho, 201 TI, 213 Bi, 212 Bi, 225 Ac, 223 Ra, 212 Pb, 211 At 124 I. 123 I. 125 I. 131 I. 18 F. 186 Re, 188 Re,99m Tc and other radionuclides to achieve integrated diagnosis and treatment.
[0005] The first technical solution provided by the present invention is:
[0006] A boron-containing drug labeled with a radionuclide, obtained by labeling a boron-containing drug with at least one radionuclide;
[0007] The boron-containing drug is obtained by polymerization reaction of dopamine and its derivatives with boron-containing compounds.
[0008] Preferably, the radionuclide comprises 68 Ga, 67 Ga, 64 Cu, 67 Cu, 89 Zr, 89 Sr. 90 Y. 177 Lu, 111 In, 165 Dy, 166 Ho, 201 TI, 213 Bi, 212 Bi, 225 Ac, 223 Ra, 212 Pb, 211 At 124 I. 123 I. 125 I. 131 I. 18 F. 186 Re, 188 Re, 99m Any one or more of Tc.
[0009] Preferably, the particle size of the radionuclide-labeled boron-containing drug is 50-1000 nm.
[0010] Preferably, the boron-containing compound includes, but is not limited to, any one or more of boric acid, boric acid phenylalanine and its derivatives, boric acid proline, boric acid aspartic acid, boric acid tyrosine, boric acid cysteine, boric acid methionine, boric acid serine, 5-amino-2,3-difluorophenylboric acid, 3-amino-5-cyanophenylboric acid, 3-amino-4-methylphenylboric acid, 3-aminophenylboronic acid hydrochloride, and 4-carbamoylphenylboric acid.
[0011] Preferably, the dopamine and its derivatives include any one or more of dopamine, 4-(2-aminopropyl)benzene-1,2-diol, norepinephrine (1-(3,4-dihydroxyphenyl)-2-aminoethanol), levomethyldopa (2-methyl-3-(3,4-dihydroxyphenyl)-L-alanine), droxidopa ((2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic acid), and 5-hydroxydopamine.
[0012] Preferably, the dopamine and its derivatives are dopamine, levomethyldopa, and 5-hydroxydopamine.
[0013] Preferably, the mass ratio of the dopamine and its derivatives to the boron-containing compound is (1-10):1.
[0014] The radionuclide-labeled boron-containing drug according to any one of claims 1 to 7, characterized in that the indications of the radionuclide-labeled boron-containing drug include head and neck tumors, lung cancer, peritoneal cancer, liver cancer, gastric cancer, melanoma, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, bladder cancer, breast cancer, colon cancer, colorectal cancer, uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, vulvar cancer, and thyroid cancer.
[0015] The second technical solution provided by the present invention is:
[0016] A method for preparing a radionuclide-labeled boron-containing drug, comprising: complexing and precipitating the radionuclide with the polyhydroxyl and carboxyl groups on the boron-containing drug; or
[0017] The radioactive nuclide is labeled in the benzene ring structure of the boron-containing drug through a chemical reaction to form a covalent bond.
[0018] Compared with the prior art, the present invention has the following beneficial effects:
[0019] The radiopharmaceuticals of the present invention achieve 68 Ga, 67 Ga, 64 Cu, 67 Cu, 89 Zr, 89 Sr. 90 Y. 177 Lu, 111 In, 165 Dy, 166 Ho, 201 TI, 213 Bi, 212 Bi, 225 Ac, 223 Ra, 212 Pb, 211 At124 I. 123 I. 125 I. 131 I. 18 F. 186 Re, 188 Re, 99m Highly efficient labeling of radionuclides such as Tc, 68 Ga, 67 Ga, 90 Y. 177 Lu, 165 Dy, 166 The labeling rate of multiple nuclides such as Ho exceeds 98%, and the radioactive drug has good stability in physiological saline, phosphate buffer, and 5% fetal bovine serum. The particle size of the radioactive drug of the present invention is between 50-1000nm, with good stability, can enter cells, pass through the blood-brain barrier and has tumor targeting, and can be used for the treatment or imaging of tumors at the same time, and the drug labeled with imaging nuclides can be used for drug distribution research and screening of potential treatment patients or prediction of treatment effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 This is a SEM image of the boron-containing drug after reconstitution in Example 2;
[0021] Figure 2 For Example 4 90 SEM image of Y-labeled boron-containing drug;
[0022] Figure 3 For Example 4 90 DLS profile of Y-labeled boron-containing drugs;
[0023] Figure 4 For Example 12 131 I-labeled boron-containing drug in vivo SPECT-CT experiment in mice;
[0024] Figure 5 For the free 131 I: In vivo SPECT-CT experiment in mice. DETAILED DESCRIPTION
[0025] In order to better understand the technical solution of the present invention, the technical solution of the present invention will be further described below in conjunction with the accompanying drawings and embodiments. The mode for implementing the present invention includes but is not limited to the following embodiments, which are used to illustrate the present invention but are not used to limit the scope of protection of the present invention. Unless otherwise specified, the technical means used in the embodiments are conventional means well known to those skilled in the art. The test methods in the following embodiments, unless otherwise specified, are conventional methods.
[0026] The first embodiment provided by the present invention is a boron-containing drug labeled with a radionuclide, which is obtained by labeling the boron-containing drug with at least one radionuclide; the boron-containing drug is obtained by polymerization reaction of dopamine and its derivatives with a boron-containing compound.
[0027] The boron-containing drug and the radionuclide are labeled with the radionuclide in the form of complexation or covalent bond.
[0028] The boron-containing drug of the present invention contains polyphenols, carboxyl groups, and benzene ring structures in its molecular structure, has good tumor targeting properties, and the boron-containing drug itself has good physicochemical stability properties, and can become a radiopharmaceutical with good targeting properties after being labeled with radionuclides. The boron-containing drug of the present invention itself does not have imaging properties, and the in vivo distribution and metabolism of the boron-containing drug is a difficult point to study during drug development. The radionuclide-labeled boron-containing drug provided by the present invention has the characteristics of being able to simultaneously achieve efficient and stable labeling of multiple radionuclides, and still has good physicochemical properties and tumor targeting properties after labeling radionuclides, and has the potential to be developed into a local targeted internal irradiation diagnosis and treatment integrated drug. In addition, the imaging nuclide-labeled boron-containing drug helps to study the in vivo distribution and metabolism of the drug itself, providing assistance for the development of the boron-containing drug.
[0029] The radioactive drug of the present invention does not change the tumor targeting of the boron-containing drug and can be metabolized in the body (biodegradable). After 48 hours of injection into the body, the drug concentration decreases rapidly until it is completely metabolized and cleared.
[0030] In an embodiment of the present invention, the radioactive nuclide used for labeling comprises 68 Ga, 67 Ga, 64 Cu, 67 Cu, 89 Zr, 89 Sr. 90 Y. 177 Lu, 111 In, 165 Dy, 166 Ho, 201 TI, 213 Bi, 212 Bi, 225 Ac, 223 Ra, 212 Pb, 211 At 124 I. 123 I. 125 I. 131 I. 18 F. 186 Re, 188 Re, 99mAny one or more of Tc.
[0031] The particle size of the radionuclide-labeled boron-containing drug is usually 50-1000 nm, and has the property of being taken up by cancer cells to achieve tumor targeting.
[0032] As some preferred embodiments, the boron-containing compound includes but is not limited to any one or more of boric acid, boric acid phenylalanine and its derivatives, boric acid proline, boric acid aspartic acid, boric acid tyrosine, boric acid cysteine, boric acid methionine, boric acid serine, 5-amino-2,3-difluorophenylboric acid, 3-amino-5-cyanophenylboric acid, 3-amino-4-methylphenylboric acid, 3-aminophenylboronic acid hydrochloride, and 4-carbamoylphenylboronic acid.
[0033] As some preferred embodiments, the dopamine and its derivatives include any one or more of dopamine, 4-(2-aminopropyl)benzene-1,2-diol, norepinephrine (1-(3,4-dihydroxyphenyl)-2-aminoethanol), levomethyldopa (2-methyl-3-(3,4-dihydroxyphenyl)-L-alanine), droxidopa ((2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic acid), and 5-hydroxydopamine; more preferably, dopamine, levomethyldopa, and 5-hydroxydopamine.
[0034] In some preferred embodiments, the mass ratio of the dopamine and its derivatives to the boron-containing compound is (1-10):1.
[0035] The indications of the radionuclide-labeled boron-containing drug of the present invention include head and neck tumors, lung cancer, peritoneal cancer, liver cancer, gastric cancer, melanoma, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, bladder cancer, breast cancer, colon cancer, colorectal cancer, uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, vulvar cancer, thyroid cancer and other diseases.
[0036] The second embodiment of the present invention provides a method for preparing a boron-containing drug labeled with a radionuclide, which can be implemented in two forms: 1. Complexation of the metal radionuclide and further precipitation and solidification are achieved through multiple hydroxyl groups, carboxyl groups, etc. on the boron-containing drug, thereby achieving stable labeling. 2. Labeling the radionuclide in the benzene ring structure of the boron-containing drug through chemical reaction to form a covalent bond to achieve stable labeling. There is no particular limitation on the specific labeling method, as long as the above two types of labeling can be achieved.
[0037] As some specific embodiments, the method of labeling a radionuclide on a boron-containing drug by complexation is at least applicable to 68 Ga, 67 Ga, 64 Cu, 67 Cu,89 Zr, 89 Sr. 90 Y. 177 Lu, 111 In, 165 Dy, 166 Ho, 201 TI, 213 Bi, 212 Bi, 225 Ac, 223 Ra, 212 For radioactive nuclides such as Pb, the specific method is as follows: weigh 10-100 mg of boron-containing drugs, add a buffer solution of pH 3.0-7.0, and mix by ultrasonication; add 0.1-500 mCi of radionuclide solution to the ultrasonically treated solution, and react for 5-60 minutes in a water bath at 30-80°C to allow the boron-containing drug to fully combine with the nuclide; centrifuge the fully combined mixed solution to obtain a solid, wash it three times with a buffer solution, collect the supernatant and precipitate, and measure their radioactivity respectively, and calculate the labeling rate of the radionuclide-labeled boron-containing drug. Boron-containing drugs labeled with radionuclides of a certain activity are placed in physiological saline, phosphate buffer, and 5% fetal bovine serum, respectively, and allowed to stand at 37°C for a period of time. The supernatant is taken to measure the activity or radioactivity count, and the radionuclide leakage rate of the drug in different solutions is calculated. After testing, 68 Ga, 67 Ga, 90 Y. 177 Lu, 165 Dy, 166 The labeling rate of multiple radionuclides such as Ho exceeded 98%, and the radionuclide leakage rate was less than 5% after 6 days in normal saline, phosphate buffer, and 5% fetal bovine serum.
[0038] The method of labeling radionuclides on boron-containing drugs by complexation is also applicable to 186 Re, 188 Re, 99m The specific method is as follows: 4-500 mg of sodium ascorbate, 100 mg of sodium tc and 100 mg of sodium tc are added to a sodium acetate buffer solution (pH 3.0-6.0) containing 5-100 mg of nanoparticles. 186 ReO4 / Na 188 ReO4 / Na 99m TcO40.1-100mCi, 80℃ oscillation reaction for 15min, centrifugation to obtain solid, wash with buffer solution 3 times, collect supernatant and precipitate, and measure their radioactivity respectively, calculate the labeling rate of radionuclide labeled boron-containing drugs. After testing, 186 Re, 188 Re, 99mThe labeling rate of Tc is greater than 85%, and the radioactive drug of the present invention can be used for the treatment of tumors.
[0039] As other specific embodiments, the method of labeling a radionuclide on a boron-containing drug by covalent reaction is at least applicable to 211 At 124 I. 123 I. 125 I. 131 I and other radionuclides, the specific method is: dissolve chloramine T in an organic solvent, apply it to the bottom of the tube, and dry; place 5-10 mg of boron-containing drugs and a buffer solution of pH 7.0-8.0 in a reaction tube, ice bath, add radionuclides to react for 5-30 minutes; centrifuge the mixed solution after the reaction, wash the precipitate multiple times, and measure the total radioactivity in the supernatant and precipitate, respectively, and calculate the labeling rate of the radionuclide-labeled boron-containing drugs. Drugs of a certain activity are placed in physiological saline, phosphate buffer, and 5% fetal bovine serum, respectively, and allowed to stand at 37°C for a period of time. The supernatant is taken to measure the activity or radioactivity count, and the radionuclide leakage rate of the drug in different solutions is calculated. After testing, 131 I and 123 The labeling rate of I exceeds 85%, the labeling amount is greater than 10mCi / mg, the labeling is stable, the nuclide does not fall off significantly in vivo, and the therapeutic effect on tumors is outstanding. After standing for 48 hours in physiological saline, phosphate buffer, and 5% fetal bovine serum, the leakage rate of the nuclide is less than 1%.
[0040] The method of labeling a radionuclide on a boron-containing drug by covalent reaction is also applicable to 18 F and other radionuclides, the specific method is: evenly disperse the boron-containing drug in a trifluoroacetic acid solution, 18 F2 gas was bubbled into the solution to react. After half an hour of reaction, the precipitate was collected and its radioactivity was measured to calculate the labeling rate of the boron-containing drug. 18 The labeling rate of F is greater than 70%, which can be used for the in vivo distribution study of boron-containing drugs.
[0041] The preparation method of the boron-containing drug comprises: mixing an aqueous solution of dopamine and its derivatives with an aqueous solution of a boron-containing compound for reaction, separating the solid from the liquid to obtain a solid, washing the solid, and freeze-drying the solid.
[0042] As some preferred implementations, the pH of the mixed reaction is 6 to 14, the mixed reaction time is 0.5 to 48 hours, and the stirring speed during the reaction is above 200 rpm.
[0043] The third embodiment of the present invention provides the use of a radionuclide-labeled boron-containing drug in the preparation of a drug for tumor treatment and / or tumor imaging. That is, the drug can not only achieve tumor treatment or tumor imaging, but also achieve an integrated tumor diagnosis and treatment drug. The drug labeled with imaging nuclides of the present invention can be used for drug distribution research and screening of potential treatment patients or prediction of treatment effects.
[0044] The present invention is based on the composition and structural design of the boron-containing drug, so that the boron-containing drug becomes a good radionuclide carrier, so that the radionuclide labeling can be achieved through a simple nuclide labeling method. After labeling the radionuclide for imaging and / or treatment, the boron-containing drug can be used for the diagnosis and treatment of tumor patients.
[0045] The present invention is achieved by 211 At 124 I. 123 I. 125 I. 131 I and 18 Boron-containing drugs labeled with radionuclides such as F can be imaged under SPECT-CT and used for the study of the in vivo distribution of boron-containing drugs, helping to understand the dynamic distribution information of boron-containing drugs in patients. 211 At 124 I. 123 I. 125 I. 131 I and 18 Boron-containing drugs labeled with radionuclides such as F can be used for pre-treatment screening and efficacy prediction of patients, and are expected to achieve precise diagnosis and treatment. 131 This I-labeled drug is expected to be used in the integrated diagnosis and treatment of tumors.
[0046] 131 After the boron-containing drug labeled with I was injected intravenously, SPECT-CT imaging showed that the drug was enriched in the tumor at a high concentration at about 24 hours, indicating that radionuclide labeling did not change the tumor targeting of the boron-containing drug, and no obvious changes were observed in the animal thyroid gland. 131 I enrichment, proof 131 I-labeled drugs are not enriched in the thyroid gland, and the 131 I No obvious shedding occurred.
[0047] In order to make the technical solution of the present invention clearer, the boron-containing drug labeled with radionuclides, its preparation method and application are described below through a number of specific embodiments.
[0048] Example 1 Preparation of Boron-Containing Drugs
[0049] Weigh 80 mg of dopamine hydrochloride into a reaction bottle, add 34 ml of 30% ethanol solution, and stir to dissolve; weigh 20 mg of 4-boronic acid-L-phenylalanine (BPA) into a centrifuge tube, add 3 ml of water, and then add 0.2 ml of 2.5 mol / L NaOH solution to completely dissolve BPA; mix the solutions, adjust the pH to about 10 with NaOH, and stir at 300 rpm for 24 hours; centrifuge at 10,000 rpm, wash three times with pure water; suspend the product in water and lyophilize to obtain the boron-containing drug.
[0050] Example 2 Redissolution experiment of boron-containing drugs after freeze-drying
[0051] Take 5 mg of the boron-containing drug in Example 1, add 5 mL of solvent including but not limited to sterile water for injection, sodium chloride injection, glucose injection, PBS buffer, water as one of the dispersants, mix manually and then perform SEM detection. The morphology characterization is shown in Figure 1 .
[0052] Example 3 Preparation of Radiopharmaceuticals
[0053] This example is used to illustrate 68 Ga labeling process: Weigh 5 mg of the boron-containing drug in Example 1, add 2 ml of sodium acetate buffer solution with pH = 5.5, and mix by ultrasonic. Add 500 μCi of 68 The GaCl3 solution was shaken in a 50°C water bath for 50 minutes. After centrifugation, the supernatant and precipitate were washed three times with pH=5.5 sodium acetate buffer, and their radioactivity was measured respectively. The radionuclide labeling rate of the boron-containing drug was calculated to be greater than 99%. The precipitate was placed in physiological saline, phosphate buffer, and 5% fetal bovine serum, respectively, and allowed to stand at 37°C for 24 hours. The supernatant and precipitate were centrifuged, washed three times with pH=5.5 sodium acetate buffer, and the supernatant and precipitate were collected. Their radioactivity was measured respectively, and the leakage rate of the boron-containing drug was calculated to be less than 1%.
[0054] Example 4 Preparation of Radiopharmaceuticals
[0055] This example is used to illustrate 90 Y labeling process: weigh 5 mg of the boron-containing drug in Example 1, add 2 ml of sodium acetate buffer solution with pH = 5.5, and mix by ultrasonic. Add 500 μCi of 90The YCI3 standard solution was shaken in a 50°C water bath for 50 minutes. After centrifugation, the supernatant and precipitate were washed three times with pH=5.5 sodium acetate buffer, and their radioactivity was measured respectively. The labeling rate of the boron-containing drug was calculated to be greater than 98%. The precipitate was placed in physiological saline, phosphate buffer, and 5% fetal bovine serum, respectively, and allowed to stand at 37°C for 6 days. The supernatant and precipitate were centrifuged, washed three times with pH=5.5 sodium acetate buffer, and the supernatant and precipitate were collected. The radioactivity was measured respectively, and the leakage rate of the boron-containing drug was calculated to be less than 1%.
[0056] In this embodiment 90 The SEM image of Y-labeled boron-containing drug is shown in Figure 2 As shown in the DLS diagram Figure 3 shown.
[0057] Example 5 Preparation of Radiopharmaceuticals
[0058] This example is used to illustrate 177 Lu labeling process: weigh 5 mg of the boron-containing drug in Example 1, add 2.5 ml of sodium acetate buffer solution with pH = 5.5, and mix by ultrasonic. Add 500 μCi of 177 LuCI3 standard solution was shaken in a 50℃ water bath for 50min. The supernatant and precipitate were separated by centrifugation, washed 3 times with sodium acetate buffer at pH=5.5, the supernatant and precipitate were collected, and their radioactivity was measured respectively. The labeling rate of boron-containing drugs was calculated to be greater than 99%. The precipitate was placed in physiological saline, phosphate buffer, and 5% fetal bovine serum, respectively, and allowed to stand at 37℃ for 6d. The supernatant and precipitate were separated by centrifugation, washed 3 times with sodium acetate buffer at pH=5.5, the supernatant and precipitate were collected, and their radioactivity was measured respectively. The leakage rate of boron-containing drugs was calculated to be less than 1%.
[0059] Example 6 Preparation of Radiopharmaceuticals
[0060] This example is used to illustrate 64 Cu, 67 Cu, 89 Zr, 89 Sr. 111 In, 165 Dy, 166 Ho, 201 TI, 213 Bi, 212 Bi, 225 Ac, 223 Ra, 212 The marking effect of Pb, the marking process is shown in Example 4, and the marking rate and leakage rate are shown in Table 1.
[0061] Table 1 Labeling rate and leakage rate of metal nuclides labeled with nanoparticles
[0062] .
[0063] Example 7 Preparation of Radiopharmaceuticals
[0064] This example is used to illustrate 131 I marking process: dissolve chloramine T in an organic solvent, apply it to the bottom of the tube, and dry it. Disperse 25 mg of the boron-containing drug of Example 1 evenly in 10 ml of PBS buffer solution and place it in a reaction tube. Place the reaction tube in an ice bath and add 131 I solution 5mCi reaction for 10min. Ultrafiltration was used to measure the ultrafiltration tube and overall activity, and the labeling rate was greater than 95%. The precipitate was placed in physiological saline, phosphate buffer, and 5% fetal bovine serum, respectively, and allowed to stand at 37℃ for 48h. The supernatant and precipitate were separated by centrifugation, and washed three times with sodium acetate buffer at pH=5.5. The supernatant and precipitate were collected, and their radioactivity was measured respectively. The leakage rate of the boron-containing drug was calculated to be less than 1%.
[0065] Example 8 Preparation of Radiopharmaceuticals
[0066] This example is used to illustrate 123 I marking process: dissolve chloramine T in an organic solvent, apply it to the bottom of the tube, and dry it. Disperse 5 mg of the boron-containing drug of Example 1 evenly in 2 ml of PBS buffer solution and place it in a reaction tube. Place the reaction tube in an ice bath and add 123 1 mCi of I solution was reacted for 10 min. The ultrafiltration tube and overall activity were measured by ultrafiltration, and the labeling rate was 86%.
[0067] Example 9 Preparation of Radiopharmaceuticals
[0068] This example is used to illustrate 18 F labeling process: 2.5 mg of boron-containing drug was dissolved in a mixed solution of 0.6 ml of trifluoroacetic acid and 0.9 ml of trichlorofluoromethane. 18 F]F2 gas and neon gas were injected into the solution together, trifluoroacetic acid and 0.9 ml of trichlorofluoromethane were evaporated under the neon environment, the residual nanoparticles were collected, their radioactivity was measured and the labeling rate was calculated, which was 71%.
[0069] Example 10 Preparation of Radiopharmaceuticals
[0070] This example is used to illustrate 99m Tc labeling process: 4 mg sodium ascorbate, 4 mg Na 99m TcO41mCi, oscillation reaction at 80℃ for 15min, target nuclide labeling was achieved, with a labeling rate of 85%.
[0071] Example 11 In vivo distribution experiment of boron-containing drugs in a mouse subcutaneous brain glioma model
[0072] The boron-containing drug of Example 1 was injected into tumor-bearing mice via the tail vein at a dose of 150 mg / kg. At 12h, 24h and 36h after administration, normal tissues of the heart, liver, spleen, lung, kidney, blood, brain, tumor and tumor margin of the mice were taken respectively, and each tissue was weighed and digested. The boron concentration in each organ was measured by ICP-MS. At 24h, the boron concentration in the tumor site reached 74μg / g, and the T / N ratio was as high as 70:1. The distribution of boron in mice at 12h, 24h and 36h after administration is shown in Table 2.
[0073] Table 2 Distribution of boron in mice 12h, 24h and 36h after administration
[0074] .
[0075] This example studies the distribution of subcutaneous brain glioma model animals, and the boron-containing drug is significantly taken up at the tumor site.
[0076] Example 12 SPECT-CT Experiment
[0077] In Example 7, about 0.2 mCi 131 The boron-containing drug labeled with I was injected into the tumor-bearing mice via the tail vein. After the injection, static acquisition was performed for 10 minutes at 9h, 18h, 24h and 48h to obtain SPECT-CT image data. The results are as follows: Figure 4 As shown. Free 131 I was injected into tumor-bearing mice through the tail vein, and the SPECT-CT image data were obtained by static acquisition for 10 minutes. Figure 5 It is mainly metabolized by the kidney and bladder. Except for the major metabolic organs such as the gallbladder, kidney, and bladder, there is no obvious uptake in other normal tissues, and the uptake is obvious in the tumor site, indicating that radionuclide labeling does not affect the uptake of boron-containing drugs in the tumor site.
[0078] Embodiment 13 131 Treatment of subcutaneous brain glioma in mice with I-labeled boron-containing drugs
[0079] Inject physiological saline and about 2 mCi of Example 7 131 The boron-containing drug labeled with I was injected into tumor-bearing mice via tail vein, and the volume of subcutaneous brain glioma of the mice was measured on the 3rd, 5th and 10th days. The specific results are shown in Table 3. 131 I-labeled boron-containing drugs can significantly inhibit tumor growth.
[0080] Table 3 Volume of subcutaneous glioma in mice
[0081] .
[0082] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. However, these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A boron-containing drug labeled with radioactive nuclides, characterized in that: Obtained by labeling a boron-containing drug with at least one radionuclide; The boron-containing drug is obtained by polymerization reaction of dopamine and its derivatives with a boron-containing compound; The boron-containing compound includes any one or more of boric acid, phenylalanine borate, proline borate, tyrosine borate, 5-amino-2,3-difluorophenylboric acid, 3-amino-5-cyanophenylboric acid, 3-amino-4-methylphenylboric acid, 3-aminophenylboric acid hydrochloride, and 4-carbamoylphenylboric acid; The dopamine and its derivatives include any one or more of dopamine, norepinephrine, levomethyldopa, droxidopa, and 5-hydroxydopamine.
2. The radionuclide-labeled boron-containing drug according to claim 1, characterized in that: The boric acid phenylalanine is 4-boronic acid-L-phenylalanine.
3. The radionuclide-labeled boron-containing drug according to claim 1, characterized in that: The radionuclides include 68 Ga, 67 Ga, 64 Cu, 67 Cu, 89 Zr, 89 Sr. 90 Y. 177 Lu, 111 In, 165 Dy, 166 Ho, 201 TI, 213 Bi, 212 Bi, 225 Ac, 223 Ra, 212 Pb, 211 At 124 I. 123 I. 125 I. 131 I. 18 F. 186 Re, 188 Re, 99m Any one or more of Tc.
4. The radionuclide-labeled boron-containing drug according to claim 1, characterized in that: The particle size of the radionuclide-labeled boron-containing drug is 50-1000 nm.
5. The radionuclide-labeled boron-containing drug according to claim 1, characterized in that: The dopamine and its derivatives are dopamine, levomethyldopa and 5-hydroxydopamine.
6. The radionuclide-labeled boron-containing drug according to claim 1, characterized in that: The mass ratio of the dopamine and its derivatives to the boron-containing compound is (1-10):
1.
7. The boron-containing drug labeled with a radionuclide according to any one of claims 1 to 6, characterized in that: The indications of the radionuclide-labeled boron-containing drug include head and neck tumors, lung cancer, peritoneal cancer, liver cancer, gastric cancer, melanoma, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, bladder cancer, breast cancer, colorectal cancer, uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, and vulvar cancer.
8. The radionuclide-labeled boron-containing drug according to claim 7, characterized in that: The head and neck tumor is thyroid cancer.
9. A method for preparing a boron-containing drug labeled with a radionuclide as claimed in any one of claims 1 to 8, characterized in that: Including: complexing, precipitation and solidification of radionuclides through polyhydroxyl and carboxyl groups on boron-containing drugs; or The radioactive nuclide is labeled in the benzene ring structure of the boron-containing drug through a chemical reaction to form a covalent bond.
10. Use of the boron-containing drug labeled with a radionuclide according to any one of claims 1 to 8 in the preparation of drugs for tumor treatment and / or tumor imaging.
